$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2020 Form 10-K Financial Statement

#000110465921011928 Filed on February 04, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.360M $1.480M $5.800M
YoY Change 61.38% -6.33% 0.52%
% of Gross Profit
Research & Development $22.33M $6.190M $17.20M
YoY Change 29.79% 60.36% 107.45%
% of Gross Profit
Depreciation & Amortization $219.0K $50.00K $164.0K
YoY Change 33.54% 150.0% 49.09%
% of Gross Profit
Operating Expenses $22.33M $7.670M $17.20M
YoY Change 29.79% 40.99% 107.45%
Operating Profit -$31.68M -$23.00M
YoY Change 37.75% 63.56%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$130.0K -$30.00K -$250.0K
YoY Change -48.0% -160.0% -308.33%
Pretax Income -$31.81M -$7.690M -$4.378M
YoY Change 626.61% 42.94% 21.04%
Income Tax
% Of Pretax Income
Net Earnings -$31.81M -$7.690M -$23.25M
YoY Change 36.8% 42.94% 66.71%
Net Earnings / Revenue
Basic Earnings Per Share -$1.07
Diluted Earnings Per Share -$1.07 -$338.2K -$1.061M
COMMON SHARES
Basic Shares Outstanding 29.85M
Diluted Shares Outstanding 29.85M

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.94M $570.0K $570.0K
YoY Change 7257.89% -91.93% -91.93%
Cash & Equivalents $37.83M $536.0K $540.0K
Short-Term Investments $4.110M $30.00K $30.00K
Other Short-Term Assets $1.000M $440.0K $440.0K
YoY Change 127.27% -63.03% -63.03%
Inventory
Prepaid Expenses $276.0K
Receivables $220.0K $2.360M $2.270M
Other Receivables $80.00K $0.00 $90.00K
Total Short-Term Assets $43.24M $3.360M $3.360M
YoY Change 1186.9% -67.28% -67.28%
LONG-TERM ASSETS
Property, Plant & Equipment $7.990M $960.0K $3.140M
YoY Change 154.46% 47.47% 383.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $30.00K $3.174M $30.00K
YoY Change 0.0% 231.32% -90.32%
Total Long-Term Assets $8.020M $3.174M $3.170M
YoY Change 153.0% 231.32% 230.21%
TOTAL ASSETS
Total Short-Term Assets $43.24M $3.360M $3.360M
Total Long-Term Assets $8.020M $3.174M $3.170M
Total Assets $51.26M $6.534M $6.530M
YoY Change 684.99% -41.81% -41.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.420M $14.68M $14.68M
YoY Change -63.08% 222.71% 222.64%
Accrued Expenses $3.920M $1.000M $2.260M
YoY Change 73.45% -4.03% 117.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.23M $17.65M $17.65M
YoY Change -36.37% 184.19% 184.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.560M $1.100M $1.100M
YoY Change 314.55%
Total Long-Term Liabilities $4.560M $1.103M $1.100M
YoY Change 314.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.23M $17.65M $17.65M
Total Long-Term Liabilities $4.560M $1.103M $1.100M
Total Liabilities $15.80M $18.76M $18.76M
YoY Change -15.78% 201.95% 202.09%
SHAREHOLDERS EQUITY
Retained Earnings -$117.3M
YoY Change 24.73%
Common Stock $105.1M
YoY Change 11.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.46M -$12.22M -$12.22M
YoY Change
Total Liabilities & Shareholders Equity $51.26M $6.534M $6.530M
YoY Change 684.99% -41.81% -41.85%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$31.81M -$7.690M -$23.25M
YoY Change 36.8% 42.94% 66.71%
Depreciation, Depletion And Amortization $219.0K $50.00K $164.0K
YoY Change 33.54% 150.0% 49.09%
Cash From Operating Activities -$35.19M -$3.280M -$11.25M
YoY Change 212.91% -11.83% -9.21%
INVESTING ACTIVITIES
Capital Expenditures $378.0K -$340.0K $473.0K
YoY Change -20.08% 209.09% 28.18%
Acquisitions
YoY Change
Other Investing Activities -$4.070M $0.00 $6.090M
YoY Change -166.83% -100.0% -816.47%
Cash From Investing Activities -$4.452M -$340.0K $5.616M
YoY Change -179.27% -108.56% -561.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$27.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 76.94M 2.070M 5.225M
YoY Change 1372.5% -56.69%
NET CHANGE
Cash From Operating Activities -35.19M -3.280M -11.25M
Cash From Investing Activities -4.452M -340.0K 5.616M
Cash From Financing Activities 76.94M 2.070M 5.225M
Net Change In Cash 37.29M -1.550M -406.0K
YoY Change -9285.47% -720.0% -73.65%
FREE CASH FLOW
Cash From Operating Activities -$35.19M -$3.280M -$11.25M
Capital Expenditures $378.0K -$340.0K $473.0K
Free Cash Flow -$35.57M -$2.940M -$11.72M
YoY Change 203.51% -18.56% -8.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
CY2020 dei City Area Code
CityAreaCode
201
CY2020 dei Entity File Number
EntityFileNumber
001-36641
CY2020 dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35159977
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23174228
CY2020 bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001137883
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Local Phone Number
LocalPhoneNumber
488-0460
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
CY2020 dei Trading Symbol
TradingSymbol
BCLI
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
278374634
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35721429
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37829000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
536000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
4107000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
33000
CY2020Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
304000
CY2019Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2359000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1002000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
432000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
43242000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3360000
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
26000
CY2019Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
32000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6872000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2182000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1119000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
960000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8017000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3174000
CY2020Q4 us-gaap Assets
Assets
51259000
CY2019Q4 us-gaap Assets
Assets
6534000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5417000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14677000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1261000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1000000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2655000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1263000
CY2020Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1900000
CY2019Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
714000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11233000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17654000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4562000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1103000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4562000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1103000
CY2020Q4 us-gaap Liabilities
Liabilities
15795000
CY2019Q4 us-gaap Liabilities
Liabilities
18757000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35159977
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23174228
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
184655000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
105042000
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2019Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
0
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149087000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117276000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35464000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51259000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6534000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22329000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17204000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9355000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5797000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-31684000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-23001000
CY2020 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
127000
CY2019 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
252000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-31811000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-23253000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29848217
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21906257
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
5016000
CY2019 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
25000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
764000
CY2019 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
2064000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3126000
CY2019 bcli Stock Issued During Period Value Exercise And Reissuance Of Warrants
StockIssuedDuringPeriodValueExerciseAndReissuanceOfWarrants
35000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-23253000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2560000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9957000
CY2020 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
116000
CY2020 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
60729000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
68000
CY2020 bcli Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
6300000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-31811000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35464000
CY2020 us-gaap Profit Loss
ProfitLoss
-31811000
CY2019 us-gaap Profit Loss
ProfitLoss
-23253000
CY2020 us-gaap Depreciation
Depreciation
219000
CY2019 us-gaap Depreciation
Depreciation
164000
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
25000
CY2020 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2560000
CY2019 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
764000
CY2020 bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
161000
CY2019 bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
184000
CY2020 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1491000
CY2019 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-690000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-9260000
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
10129000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1447000
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
50000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35193000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11247000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
378000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
473000
CY2020 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
4074000
CY2019 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-6089000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4452000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5616000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
68000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35000
CY2020 bcli Proceeds From At Market
ProceedsFromAtMarket
60729000
CY2019 bcli Proceeds From At Market
ProceedsFromAtMarket
2064000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9957000
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
116000
CY2020 bcli Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
6300000
CY2019 bcli Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
3126000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
76938000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5225000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37293000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-406000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
536000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
942000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37829000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
536000
CY2020 bcli Right Of Use Lease Asset And Liability
RightOfUseLeaseAssetAndLiability
-5857000
CY2019 bcli Right Of Use Lease Asset And Liability
RightOfUseLeaseAssetAndLiability
-3197000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 57.6pt;">B.          Use of estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 93.6pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.0833
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
600000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7217000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6872000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2182000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7217000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2366000
CY2020 us-gaap Lease Cost
LeaseCost
1423000
CY2020 bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
CY2020 bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
84000
CY2019Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
90000
CY2020Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
304000
CY2019Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2359000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
276000
CY2020Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
984000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6872000
CY2019 us-gaap Lease Cost
LeaseCost
1296000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y11M4D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0700
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000000.0
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1423000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5857000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y11M4D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0700
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2760000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1422000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1437000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1406000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1265000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8290000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1073000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7217000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3072000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3366665
CY2019Q3 bcli Fixed Commission Percentage
FixedCommissionPercentage
500000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2694000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1953000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1734000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1119000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
960000
CY2020 us-gaap Depreciation
Depreciation
219000
CY2019 us-gaap Depreciation
Depreciation
164000
CY2020 bcli Grants Underlying Basis
GrantsUnderlyingBasis
The grant is linked to the exchange rate of the dollar and bears interest of Libor per annum.
CY2019 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P4M
CY2020 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P4M
CY2007Q3 bcli Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
672222
CY2019Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3300000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1250000
CY2020Q1 us-gaap Share Price
SharePrice
8.00
CY2020Q1 bcli Warrant Term
WarrantTerm
P3Y
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
143000
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3018413
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.57
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.66
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.60
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0031
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0057
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0144
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2386000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M17D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1754894
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1293007
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M19D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M25D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
998527
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
823007
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
25000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2560000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
789000
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
25808000
CY2019Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
24741000
CY2020 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
274000
CY2019 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
366000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22329000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17204000
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.13
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
99818000
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
73260000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26664000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19911000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26664000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19911000
CY2020Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
99818000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8578000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-4378000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-23233000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-18875000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-31811000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-23253000

Files In Submission

Name View Source Status
0001104659-21-011928-index-headers.html Edgar Link pending
0001104659-21-011928-index.html Edgar Link pending
0001104659-21-011928.txt Edgar Link pending
0001104659-21-011928-xbrl.zip Edgar Link pending
bcli-20201231.xsd Edgar Link pending
bcli-20201231x10k.htm Edgar Link pending
bcli-20201231x10k001.gif Edgar Link pending
bcli-20201231x10k003.jpg Edgar Link pending
bcli-20201231x10k_htm.xml Edgar Link completed
bcli-20201231xex10d63.htm Edgar Link pending
bcli-20201231xex10d63001.jpg Edgar Link pending
bcli-20201231xex21.htm Edgar Link pending
bcli-20201231xex23d1.htm Edgar Link pending
bcli-20201231xex23d1001.jpg Edgar Link pending
bcli-20201231xex23d1002.jpg Edgar Link pending
bcli-20201231xex31d1.htm Edgar Link pending
bcli-20201231xex31d2.htm Edgar Link pending
bcli-20201231xex32d1.htm Edgar Link pending
bcli-20201231xex32d2.htm Edgar Link pending
bcli-20201231_cal.xml Edgar Link unprocessable
bcli-20201231_def.xml Edgar Link unprocessable
bcli-20201231_lab.xml Edgar Link unprocessable
bcli-20201231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending